Blood Cancer Talks

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed: 1. ASH choosing wisely:   https://www.hematology.org/education/clinicians/guidelines-and-quali...

In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes: 2:11 How to diagnose mantle cell lymphoma (MCL)? 6:51 Clinical manifestations of mantle cell lymphoma 7:52 How to manage leukemic variant of MCL?  12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67? 17:21 Overview on treatment of newly di...

In this episode, we discuss the management of multiple myeloma in LMICs with Dr. Andrés Gómez-De León from UANL, Monterrey, Mexico, and Dr. Aditya Jandial from PGIMER, Chandigarh, India. This episode was inspired by an article in Lancet Haematology titled “ The Underrepresented Majority ”, which highlighted the lack of access to some of the basic anti-myeloma drugs in LMICs and the resulting dispa...

In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode: 1. Risk stratification of PMF : MIPSS70 Score : http://www.mipss70score.it https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886 Genetically inspired prognostic scoring system (GIPS...

1. How I Approach Smoldering Myeloma (Vaxman and Gertz): https://ashpublications.org/blood/article/140/8/828/485274   2. Risk-Stratification Models in SMM: Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/ PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/ PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/ IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/   3....

In this episode, we discuss the management of acquired aplastic anemia with Dr. Amy DeZern. Here are the links to some of the key articles discussed in this show: 1. Review article on aplastic anemia:  https://www.nejm.org/doi/10.1056/NEJMra1413485   2. RCTs testing whether addition of cyclosporine to ATG improves outcomes in aplastic anemia: https://www.nejm.org/doi/10.1056/NEJM199105093241901 ht...

1.      Phase III ASAP trial https://ash.confex.com/ash/2022/webprogram/Paper159962.html     2.      Phase III Dauno-Double Trial https://ash.confex.com/ash/2022/webprogram/Paper157126.html     3.      Reduced venetoclax exposure :  https://ash.confex.com/ash/2022/webprogram/Paper165464.html     4 .     Menin Inhibitors in AML  https://ash.confex.com/ash/2022/webprogram/Paper164849.html https://as...

In this episode, we discuss the management of newly diagnosed DLBCL with Dr. Pallawi Torka. We also have a few bonus ASH22 updates on DLBCL. Links to articles and abstracts discussed in the episode are as follows:  1. A comprehensive review article on DLBCL: https://pubmed.ncbi.nlm.nih.gov/33657296/   2. RCT testing CHOP vs Three Intensive Regimens in DLBCL: https://www.nejm.org/doi/full/10.1056/n...

1.      Excellent paper on harmonization of performing and reporting MRD in multiple myeloma:           https://www.nature.com/articles/s41375-020-01012-4 2.     Does CR really matter in the era of MRD? Landmark paper from the Spanish Group:         https://pubmed.ncbi.nlm.nih.gov/35560160/ 3.     Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple mye...

Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the   RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML https://www.nejm.org/doi/full/10.1056/n...

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper159606.html https://ash.confex.com/ash/2022/webprogram/Paper168930.html   2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model. https://ash.confex.com/ash/2022/webprogram/Paper1...

ALPINE Trial : Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL (https://www.nejm.org/doi/full/10.1056/NEJMoa2211582)   CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (https://ash.confex.com/ash/2022/webprogram/Paper163245.html)    AVO Trial : Acalabrutinib, Venetoclax, Obinutuzumab (A...

Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment Somatic alterations in Castleman Disease: https://www.ncbi...

In this episode, we discussed the three CD19-directed chimeric antigen receptor (CAR T-cell) therapies that have been approved for relapsed/refractory aggressive large B cell lymphomas (LBCL) after two lines of therapy:  Axicabtagene ciloleucel (axi-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1707447 Tisagenlecleucel (tisa-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1804980 Lisocabtagene...

Key articles and trials discussed in the episode: 1.      Excellent review in NEJM on treatment of CLL (2020): https://www.nejm.org/doi/full/10.1056/NEJMra1908213 2.     Alliance Trial (Ibrutinib vs chemoimmunotherapy in older patients with untreated CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa1812836 3.     E1912 (Ibrutinib vs chemoimmunotherapy in younger/fit patients with CLL): https://ww...

Key papers discussed in the show:   1.     Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and 2.     Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://acsjournals.onlinelibrary.wiley.com/doi/1...

Key papers discussed in the show: 1. Landmark paper on HLA-mismatch and survival: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568127/ 2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa1500140 3. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.03502 4. Review/perspective on fundamentals of unrelated donors and co...

In this episode, we do a thought provoking discussion with Dr. Marty Tallman on mentorship and career development in academic hematology and medical oncology. A must listen for all trainees and early career clinical investigators. Sage wisdom from a legend in the field!

2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/ Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006

https://ascopubs.org/doi/abs/10.1200/JCO.22.00495

In this episode, we discuss with Dr. Surbhi Sidana the latest advances, practical aspects of patient management, and future directions of cellular therapies in multiple myeloma.

In this episode, we bring two experts in clonal hematopoiesis, Dr. Sid Jaiswal from Stanford University and Dr. Alex Bick from Vanderbilt University to dissect the biology, potential clinical implications, and future of clonal hematopoiesis.

BloodCancerTalks is a new podcast focusing exclusively on hematologic malignancies. We will bring a wide range of experts to dig deep into specific topics and critically appraise the literature. Raj Chakraborty is a hematologist/oncologist and an Assistant Professor of Medicine at Columbia University. Ash Kishtagari is a hematologist/oncologist and an Assistant Professor of Medicine at Vanderbilt...